Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene
about
Review of screening for pancreatic cancer in high risk individualsGenetic alterations in pancreatic carcinomaIs metastatic pancreatic cancer an untargetable malignancy?Mouse models of pancreatic cancerPancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parametersSome molecular and clinical aspects of genetic predisposition to malignant melanoma and tumours of various site of originFamilial malignant melanoma - overviewHigh risk factors of pancreatic carcinoma.Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.Uterine serous carcinoma: increased familial risk for lynch-associated malignanciesMolecular technology and pancreatic cancer.Pancreatic adenocarcinoma: epidemiology and genetics.Melanoma epidemiology, biology and prognosis.The genetics of hereditary melanoma and nevi. 1998 update.Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer.Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients.Risk factors for pancreatic adenocarcinoma and prospects for screening.Inherited predisposition to pancreatic cancer.The FAMMM syndrome: epidemiology and surveillance strategies.Genetic predisposition to pancreatic cancer.Pancreatic adenocarcinomaA single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone familiesThe role of genetic factors in the etiology of pancreatic adenocarcinoma: an update.Negative methylation status of vimentin predicts improved prognosis in pancreatic carcinoma.Genetics of familial melanoma: 20 years after CDKN2A.Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.A common variant of CDKN2A (p16) predisposes to breast cancer.Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancerGuidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma.The CDKN2A (p16) gene and human cancer.Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in CaucasiansRetrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma.No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours.Appearance of malignant melanoma after a non-cutaneous cancer diagnosis.Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic TumorsThe complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting.Genetic and environmental factors in head and neck cancer genesis.
P2860
Q24630198-6AC4CA55-4860-4D15-867A-2221C050A0CDQ24801465-CA90F2CF-9D07-49BE-A1B0-1B5C636FF7A2Q26753849-1F1A1983-0855-49E3-9006-3AB5B4331CDCQ26860574-ECD94F5E-E0F4-4B26-89BB-1E265B713452Q27022231-9421E3B5-6917-46E2-93BD-4ABF3DCDDB7EQ28390768-69D92FDB-B3C4-4EDC-ADC7-2E66A816AEA9Q28391589-0BA58D09-BBA6-4C8E-A8C8-1B14AF0719B0Q30249161-D74CCCB4-4598-4243-8A5C-63DAEEB9AD27Q30322978-92404970-B5CA-4926-BAE3-2F5493D0258BQ30422098-0FECAFF4-716B-4CB3-86A5-D6968189CF5AQ31800438-0A9AA350-07F8-4522-BB7E-B8CDCD8904CCQ33677968-70D89821-AEA3-404D-8909-B3F545B27C45Q33698718-59866FE2-ED4C-4F95-A372-734F0652A34FQ33813969-3B1B2F16-4B98-4D75-892C-7BD659B86B39Q33862088-4249CBEF-788E-497D-B313-F4C86646AE3DQ33889751-86F6AF1C-2CDA-4CE9-A04F-8558B8FB084CQ33916380-FEF60FC4-013D-421E-85DC-7EE6141EE063Q33931174-75DF8EBD-08DE-420F-BE0F-C785DC23A19CQ34063273-572C6F51-EDCB-45BD-B799-AE1B966A23B5Q34067868-34749853-58A8-42E1-BA3E-312B67592DE6Q34140498-DBA32E66-DC3B-4543-ACCD-4910AE6D13D8Q34142079-0706778B-63BF-4BFB-AD2A-F38229A7325FQ34211033-446F29F1-F047-4C83-81A8-7EB44F55E87EQ34255579-0899D0B9-99B7-4178-ACF5-8CF3E821E2A5Q34449957-122304BC-37BD-44D3-B68A-C139E3FD286AQ34520664-6D986F70-5F97-440C-A622-5F60CA95C4ABQ34596182-8E48536A-75C0-4827-AF30-B33868E13E0BQ34642090-03E1C0F2-4249-4366-8E20-E244891BFD49Q35447197-F770A169-B20B-4DBD-B7F1-C9B9B9DB0101Q35594607-E7B37F96-655F-45A6-98BD-66575189E9C7Q35790591-2A63ECCC-4E86-4B2C-A9B9-18E8897854DDQ36347277-4778C154-028D-43D7-ABF3-6C8D5E0D2181Q36437816-4CDB7706-DE8C-494D-BEC0-01DD8C0A795CQ36627355-7DB7EAC1-CDCB-4B47-92D1-A21BDE6ADDBEQ36642335-6A5017DB-2708-4B7F-85F2-626B42AE7400Q36643968-262C3009-EE81-4764-829E-B6B2187EBF7CQ36807224-00F22F3B-EA64-437F-8B32-6465CD2ED8D7Q37017121-2992FD4F-A041-4138-8E8A-410F61CB35E1Q37156381-87716F58-CA48-473D-AC50-15F55905C8CEQ37196687-56300110-A2B0-43F1-B5AB-75F8272D1856
P2860
Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene
description
article
@en
im Oktober 1995 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 1995
@uk
ലേഖനം
@ml
name
Brief report: a familial syndr ...... he CDKN2 tumor-suppressor gene
@en
Brief report: a familial syndr ...... he CDKN2 tumor-suppressor gene
@nl
type
label
Brief report: a familial syndr ...... he CDKN2 tumor-suppressor gene
@en
Brief report: a familial syndr ...... he CDKN2 tumor-suppressor gene
@nl
prefLabel
Brief report: a familial syndr ...... he CDKN2 tumor-suppressor gene
@en
Brief report: a familial syndr ...... he CDKN2 tumor-suppressor gene
@nl
P2093
P1476
Brief report: a familial syndr ...... he CDKN2 tumor-suppressor gene
@en
P2093
A J Whelan
P J Goodfellow
P356
10.1056/NEJM199510123331505
P407
P577
1995-10-12T00:00:00Z